Mohamed F Jalloh1, Mohammad B Jalloh2, Alison Albert3, Brent Wolff3, Amy Callis3, Aparna Ramakrishnan3, Emily Cramer3, Paul Sengeh2, Samuel Abu Pratt2, Lansana Conteh4, Rana Hajjeh3, Rebecca Bunnell3, John T Redd3, Anna Mia Ekström5, Helena Nordenstedt6. 1. U.S. Centers for Disease Control and Prevention, Atlanta, GA, USA; Department of Public Health Sciences, Karolinska Institutet, Stockholm, Sweden. Electronic address: yum8@cdc.gov. 2. FOCUS 1000, Freetown, Sierra Leone. 3. U.S. Centers for Disease Control and Prevention, Atlanta, GA, USA. 4. Ministry of Health and Sanitation, Freetown, Sierra Leone. 5. Department of Public Health Sciences, Karolinska Institutet, Stockholm, Sweden; Department of Infectious diseases, Karolinska University Hospital, Sweden. 6. Department of Public Health Sciences, Karolinska Institutet, Stockholm, Sweden.
Abstract
INTRODUCTION: Experimental Ebola vaccines were introduced during the 2014-2015 Ebola outbreak in West Africa. Planning for the Sierra Leone Trial to Introduce a Vaccine against Ebola (STRIVE) was underway in late 2014. We examined hypothetical acceptability and perceptions of experimental Ebola vaccines among health care workers (HCWs), frontline workers, and the general public to guide ethical communication of risks and benefits of any experimental Ebola vaccine. METHODS: Between December 2014 and January 2015, we conducted in-depth interviews with public health leaders (N = 31), focus groups with HCWs and frontline workers (N = 20), and focus groups with members of the general public (N = 15) in Western Area Urban, Western Area Rural, Port Loko, Bombali, and Tonkolili districts. Themes were identified using qualitative content analysis. RESULTS: Across all participant groups, not knowing the immediate and long-term effects of an experimental Ebola vaccine was the most serious concern. Some respondents feared that experimental vaccines may cause Ebola, lead to death, or result in other adverse events. Among HCWs, not knowing the level of protection provided by experimental Ebola vaccines was another concern. HCWs and frontline workers were motivated to help find a vaccine for Ebola to help end the outbreak. General public participants cited positive experiences with routine childhood immunization in Sierra Leone. DISCUSSION: Our formative assessment prior to STRIVE's implementation in Sierra Leone helped identify concerns, motivations, and information gaps among potential participants of an experimental Ebola vaccine trial, at the time when an unprecedented outbreak was occurring in the country. The findings from this assessment were incorporated early in the process to guide ethical communication of risks and benefits when discussing informed consent for possible participation in the vaccine trial that was launched later in 2015. Published by Elsevier Ltd.
INTRODUCTION: Experimental Ebola vaccines were introduced during the 2014-2015 Ebola outbreak in West Africa. Planning for the Sierra Leone Trial to Introduce a Vaccine against Ebola (STRIVE) was underway in late 2014. We examined hypothetical acceptability and perceptions of experimental Ebola vaccines among health care workers (HCWs), frontline workers, and the general public to guide ethical communication of risks and benefits of any experimental Ebola vaccine. METHODS: Between December 2014 and January 2015, we conducted in-depth interviews with public health leaders (N = 31), focus groups with HCWs and frontline workers (N = 20), and focus groups with members of the general public (N = 15) in Western Area Urban, Western Area Rural, Port Loko, Bombali, and Tonkolili districts. Themes were identified using qualitative content analysis. RESULTS: Across all participant groups, not knowing the immediate and long-term effects of an experimental Ebola vaccine was the most serious concern. Some respondents feared that experimental vaccines may cause Ebola, lead to death, or result in other adverse events. Among HCWs, not knowing the level of protection provided by experimental Ebola vaccines was another concern. HCWs and frontline workers were motivated to help find a vaccine for Ebola to help end the outbreak. General public participants cited positive experiences with routine childhood immunization in Sierra Leone. DISCUSSION: Our formative assessment prior to STRIVE's implementation in Sierra Leone helped identify concerns, motivations, and information gaps among potential participants of an experimental Ebola vaccine trial, at the time when an unprecedented outbreak was occurring in the country. The findings from this assessment were incorporated early in the process to guide ethical communication of risks and benefits when discussing informed consent for possible participation in the vaccine trial that was launched later in 2015. Published by Elsevier Ltd.
Entities:
Keywords:
Acceptability; Attitudes; Ebola vaccine; Perceptions; Sierra Leone
Authors: Jeffrey C Hageman; Carmen Hazim; Katie Wilson; Paul Malpiedi; Neil Gupta; Sarah Bennett; Amy Kolwaite; Abbigail Tumpey; Kristin Brinsley-Rainisch; Bryan Christensen; Carolyn Gould; Angela Fisher; Michael Jhung; Douglas Hamilton; Kerri Moran; Lisa Delaney; Chad Dowell; Michael Bell; Arjun Srinivasan; Melissa Schaefer; Ryan Fagan; Nedghie Adrien; Nora Chea; Benjamin J Park Journal: MMWR Suppl Date: 2016-07-08
Authors: A Camacho; R M Eggo; N Goeyvaerts; A Vandebosch; R Mogg; S Funk; A J Kucharski; C H Watson; T Vangeneugden; W J Edmunds Journal: Vaccine Date: 2016-12-23 Impact factor: 3.641
Authors: Målfrid Råheim; Liv Heide Magnussen; Ragnhild Johanne Tveit Sekse; Åshild Lunde; Torild Jacobsen; Astrid Blystad Journal: Int J Qual Stud Health Well-being Date: 2016-06-14
Authors: Ana Maria Henao-Restrepo; Anton Camacho; Ira M Longini; Conall H Watson; W John Edmunds; Matthias Egger; Miles W Carroll; Natalie E Dean; Ibrahima Diatta; Moussa Doumbia; Bertrand Draguez; Sophie Duraffour; Godwin Enwere; Rebecca Grais; Stephan Gunther; Pierre-Stéphane Gsell; Stefanie Hossmann; Sara Viksmoen Watle; Mandy Kader Kondé; Sakoba Kéïta; Souleymane Kone; Eewa Kuisma; Myron M Levine; Sema Mandal; Thomas Mauget; Gunnstein Norheim; Ximena Riveros; Aboubacar Soumah; Sven Trelle; Andrea S Vicari; John-Arne Røttingen; Marie-Paule Kieny Journal: Lancet Date: 2016-12-23 Impact factor: 79.321
Authors: Mohamed F Jalloh; Aasli A Nur; Sophia A Nur; Maike Winters; Jamie Bedson; Danielle Pedi; Dimitri Prybylski; Apophia Namageyo-Funa; Kathy M Hageman; Brian J Baker; Mohammad B Jalloh; Eugenia Eng; Helena Nordenstedt; Avi J Hakim Journal: BMJ Glob Health Date: 2021-01